Feedback
Settings

Settings

Goto Application

8,578 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 858
1.WO/2025/137632ANTIBODIES AGAINST HENIPAVIRUSES
WO - 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2024/061561 Applicant MAPP BIOPHARMACEUTICAL, INC. Inventor WEST, Brandyn
Provided herein are Henipavirus antibodies. These Henipavirus antibodies bind to the Henipavirus F glycoprotein and have neutralizing activity against different Henipavirus species and strains. These antibodies are used in methods of inducing an immune response and methods of inhibiting Henipavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.
2.3216051GLUTAMIC ACID-BASED LIPIDS, LIPID NANOPARTICLE CONTAINING GLUTAMIC ACID-BASED LIPIDS, AND FORMULATIONS THEREOF
CA - 18.06.2025
Int.Class A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid , beta-alanine, epsilon-aminocaproic acid or pantothenic acid
198Alpha-amino acids, e.g. alanine or edetic acid
 Appl.No 3216051 Applicant PROVIDENCE THERAPEUTICS HOLDINGS INC. Inventor GOPALAKRISHNA PANICKER, RAJESH KRISHNAN
3.WO/2025/118598ANTI-RABIES VIRUS COMBINED MONOCLONAL ANTIBODY PREPARATION
WO - 12.06.2025
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No PCT/CN2024/105102 Applicant LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. Inventor CHEN, Jijun
Provided is an anti-rabies virus combined monoclonal antibody preparation. The present invention relates to the technical field of biomedicine. The anti-rabies virus combined monoclonal antibody preparation comprises an R92 antibody and an R71 antibody. A light chain sequence of the R92 antibody is set forth in SEQ ID NO: 1, and a heavy chain sequence of the R92 antibody is set forth in SEQ ID NO: 2. A light chain sequence of the R71 antibody is set forth in SEQ ID NO: 3, and a heavy chain sequence of the R71 antibody is set forth in SEQ ID NO: 4. The ratio of the R92 antibody to the R71 antibody in the anti-rabies virus combined monoclonal antibody preparation is (1-5):(1-5). The anti-rabies virus combined monoclonal antibody preparation has a high affinity for the rabies virus glycoprotein, has relatively good neutralizing capacity and thermal stability, and has very good neutralizing capacity against a variety of street strains. Since the two antibodies target different epitopes, the preparation can provide broader protection.
4.WO/2025/118600ANTI-RABIES VIRUS NEUTRALIZING ANTIBODY AS WELL AS PREPARATION AND USE THEREOF
WO - 12.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/CN2024/105171 Applicant LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. Inventor MAO, Xiaoyan
An anti-rabies virus neutralizing antibody and preparation and a use thereof. Provided is an anti-rabies virus neutralizing antibody, comprising a heavy chain variable region SEQ ID NO. 1-SEQ ID NO. 3, a light chain variable region SEQ ID NO. 4-SEQ ID NO. 5, and GAS. The anti-rabies virus neutralizing antibody has good neutralizing activity; a high isoelectric point provides advantages in the stability of antibody formulations; a high Tm value indicates good thermal stability; strong affinity with recombinant rabies virus glycoproteins shows promise for the mass production of rabies virus neutralizing antibodies, providing technical support for the preparation of low-cost, safe, and effective rabies passive immune formulations.
5.WO/2025/122924METHODS FOR THE PREVENTION AND TREATMENT OF LONG COVID AND RELATED SYMPTOMS
WO - 12.06.2025
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No PCT/US2024/058958 Applicant TOURMALINE BIO, INC. Inventor KULKARNI, Sandeep
The present disclosure provides methods of preventing or treating a patient having Long COVID comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti -interleukin-6 (anti-IL-6) antibody. The method described herein can prevent or treat Long COVID associated symptoms or diseases such as postural orthostatic tachycardia syndrome (POTS), brain fog, post-exertional malaise, aerobic metabolism impairment or deficiency, Chronic Fatigue Syndrome (CFS), fibromyalgia, and Mast cell activation syndrome (MCAS).
6.120118182一种靶向冠状病毒RBD蛋白的纳米抗体及其应用
CN - 10.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 202510333913.3 Applicant 南方科技大学 Inventor 傅暘
本发明提供了一种靶向冠状病毒RBD蛋白的纳米抗体及其应用，涉及生物医药技术领域，所述纳米抗体的氨基酸序列为A1～A4中的任一种。所述纳米抗体与SARS‑CoV‑2S蛋白受体结合区亲和力高，抑制SARS‑CoV‑2假病毒和真病毒感染的半数抑制浓度达到20～100nM，并且也可以有效抑制Delta变异株的感染，显示出良好的广谱中和作用；且可在大肠杆菌细胞中大量表达纯化，并且纯度非常高；将单一的纳米抗体用G4S linker进行串联表达显示出更高的中和活性和更广谱的中和能力。本发明为SARS‑CoV‑2原始毒株及其变异毒株的临床预防、治疗和检测提供了潜在的和极具应用前景的纳米抗体药物。
7.120129695新型冠状病毒XBB.1.5及相关变异株广谱中和抗体及应用
CN - 10.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 202380072168.0 Applicant 北京昌平实验室 Inventor 曹云龙
提供新型冠状病毒XBB.1.5及相关变异株广谱中和抗体及应用；应用免疫学、分子生物学、病毒学、蛋白结构分析等诸多领域的技术，获得一系列能够高效中和新型冠状病毒XBB.1.5及相关变异株的广谱中和抗体，可用于诊断、预防和治疗新型冠状病毒奥密克戎突变株感染所引发的各类疾病。
8.120118181一种抗细小病毒犬鼠嵌合抗体
CN - 10.06.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No 202510304629.3 Applicant 华中农业大学 Inventor 周红波
本发明公开了一种抗细小病毒犬鼠嵌合抗体，属于基因工程领域，该嵌合抗体包括重链可变区、轻链可变区、重链恒定区和轻链恒定区，所述重链可变区和轻链可变区为鼠源性片段，重链恒定区和轻链恒定区为犬源性片段；所述重链可变区的氨基酸序列如SEQ ID No.2所示，轻链可变区的氨基酸序列如SEQ ID No.4所示。该犬鼠嵌合抗体在体外对CPV各亚型具有广谱高中和活性，降低了鼠源抗体在犬体内的免疫排斥反应，使用该犬鼠嵌合抗体可以有效的治疗CPV‑2c感染的犬。
9.120129694用于预防和治疗正痘病毒感染的组合物和方法
CN - 10.06.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No 202380075949.5 Applicant 拜奥法克图拉公司 Inventor 达里尔·培根·桑佩
本文提供了用于治疗或预防病毒性疾病，例如痘病毒疾病，例如天花和猴痘的抗体及其功能片段。本文描述的任何抗体或其功能片段可以是工程化抗体或工程化抗体片段。此外，本文提供了含有一种或更多种抗体或其功能片段的组合物和药物组合物。本文还提供了含有一种或更多种抗体或其功能片段的试剂盒，以及施用一种或更多种抗体及其一种或更多种功能片段的方法、给药方案、剂量量和途径。最后，提供了制备抗体及其功能片段的方法。
10.120118202一种包括HMPV和HPIV-3蛋白的融合蛋白复合体、制备方法及其应用
CN - 10.06.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No 202510217242.4 Applicant 北京吉诺卫生物科技有限公司 Inventor 王希良
发明涉及一种融合蛋白复合体，所述融合蛋白复合体包括融合蛋白M，和融合蛋白P，其中，所述融合蛋白M包括HMPV的F蛋白的F2区域和F1区域以及铁蛋白的H或L链；所述融合蛋白P包括HPIV‑3的F蛋白的F2区域和F1区域以及铁蛋白的L或H链；所述融合蛋白M与所述融合蛋白P中的铁蛋白中的链为不同的链，从而可形成三聚体，用于制备疫苗，本发明的疫苗可刺激机体产生针对HMPV和HPIV的中和抗体，具有广谱性，各蛋白序列之间还具有协同作用。
# -